ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 164 | +8 | 117.28M | $20.61B | +11 | −2 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | — | 22.19M | $2.32B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 5.61M | — | $585.07M | 0.5% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 5.61M | — | $585.07M | 0.5% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 5.61M | — | $585.07M | 0.5% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 5.61M | — | $585.07M | 0.5% | n/c | 1 | SEC ↗ |
| 5 | Capital World Investors ✦ | 3.38M | — | $353.00M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 2.68M | — | $279.23M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.68M | — | $279.23M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | PRIMECAP Management ✦ | 2.43M | — | $253.51M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 2.08M | — | $217.38M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.49M | — | $155.07M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 1.39M | — | $144.67M | 0.4% | n/c | 1 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 1.00M | — | $104.41M | 0.2% | n/c | 1 | SEC ↗ |
| 13 | Marshall Wace ✦ | 743.70K | — | $77.63M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 743.70K | — | $77.63M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Icahn Capital ✦ | 430.00K | — | $44.88M | 0.4% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 426.30K | — | $44.50M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 426.30K | — | $44.50M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 161.09K | — | $16.81M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 161.09K | — | $16.81M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 144.41K | — | $15.07M | 0.1% | n/c | 1 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 112.65K | — | $11.76M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | T. Rowe Price ✦ | 112.65K | — | $11.76M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 75.56K | — | $7.89M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 75.56K | — | $7.89M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 75.56K | — | $7.89M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 75.56K | — | $7.89M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Wellington Management ✦ | 30.19K | — | $3.15M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Wellington Management ✦ | 30.19K | — | $3.15M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Gotham Asset Management ✦ | 12.53K | — | $1.31M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | GAMCO Investors ✦ | 2.46K | — | $257,297 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 837 holders, 154.80M shares, $18.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 8.19K sh · $1.78M
Director · 86.83K sh · $18.98M
Director · 133.26K sh · $29.25M
Director · 3.88K sh · $854,765
Director · 4.53K sh · $952,918
Director · 7.15K sh · $1.51M
Director · 13.05K sh · $2.78M
Director · 6.82K sh · $1.46M
Director · 13.67K sh · $2.93M
Director · 9.37K sh · $2.02M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology